VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug ...

Apr 27, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that th ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company') announced that the sNDA (the 'Application') for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

PRAGUE and LONDON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate ...

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech company. The collaboration is aimed at discovering and developing an ...

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...

One of the hotter areas of cancer drug research involves using a particular type of bispecific antibody as the backbone for therapeutic combinations intended to bring a multi-pronged attack to tumors.